Scroll down to see more

Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase


Laekna Presents Vision and Strategy at NewYorkBIO/NYSE Emerging Company Showcase


Shanghai, China and New Jersey, U.S., Dec 6, 2021 - Laekna was invited by NewYorkBIO and the New York Stock Exchange (NYSE) to present, as an emerging biotech company at the “Emerging Company Showcase” that was held earlier this month in New York

Dr. Guy Rosenthal, Vice President, Head of Corporate and Business Development of Laekna represented the company and spoke about how Laekna’s pipeline sets the company apart in the fields of cancer and liver disease drug development.

In addition, Dr. Rosenthal discussed with attendees representing the broader industry, which includes healthcare, biotech, pharmaceutical and institutional investorst, about the current state of affairs of the biopharmaceutical industry. He related to his audience how companies like Laekna are working tirelessly to advance their pipeline on the road towards commercialization.

“In times like these, we see capital markets going back to the fundamentals. Companies’ valuations are going to be derived more based on the quality and readout of their clinical data. Therefore, we are excited at Laekna to develop several clinical Oncology programs in advanced stages and we are encouraged by what we see”.



Left four of the picture is Dr. Guy Rosenthal


As the leading advocate for the life science industry in New York of USA, NewYorkBIO brings together nearly 300 of New York’s bioscience companies, universities, research institutions, and others dedicated to advancing life science research and commercialization. For the past three years, NewYorkBIO and NYSE have partnered to bring together New York's financial community with emerging biotech companies developing novel therapeutics to revolutionize patient care.


RSS Feeds
If you want to know more about Laekna, please fill in the form below and sign up for emails:
  1. Name*
  2. Email*
  3. Company
  4. Occupation



Follow us on Linkedin